Get a free sample of Anti-retroviral Drugs Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Anti-retroviral Drugs Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Anti-retroviral Drugs Market Size
Anti-Retroviral Drugs Market size was valued at USD 29.1 billion in 2023 and is anticipated to register of over 4.2% CAGR from 2024 to 2032. This growth trajectory is propelled by several factors, including increased investment in research and development, the emergence of multiple generic drug alternatives, and the advent of novel drugs boasting enhanced efficacy.
Furthermore, the mounting prevalence of HIV and the broader availability of combination anti-retroviral therapy (cART) are substantial drivers of market expansion. For instance, in July 2022, the World Health Organization (WHO) reported that around 38.4 million individuals were living with HIV globally in 2021. This uptrend in HIV cases is expected to bolster the demand for both anti-retroviral and anti-viral drugs, highlighting the crucial need for effective treatments to address the growing prevalence of the virus.
Antiretroviral drugs (ARVs) are medications used to treat infections caused by retroviruses, particularly the human immunodeficiency virus (HIV). These drugs work by targeting different stages of the HIV replication cycle, helping to suppress viral replication, reduce the viral load in the body, and slow down the progression of HIV infection to acquired immunodeficiency syndrome (AIDS).
How big is the anti-retroviral drugs industry?
Anti-retroviral drugs market size was USD 29.1 billion in 2023 and is expected to register 4.2% CAGR from 2024-2032 owing to the increased investment in research and development, and the emergence of multiple generic drug alternatives worldwide.
Why is the use of branded anti-retroviral drugs growing?
Anti-retroviral drugs market from the branded segment held 67.2% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to ongoing advancements and innovation in the development, distribution, and utilization of branded antiretroviral drugs.
Why is the demand for multi-class combination inhibitors growing?
The multi-class combination segment reached USD 7.9 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to the growing burden of HIV and new drug approvals.
Who are the key leaders in the anti-retroviral drugs industry?
AbbVie Inc., Bristol-Myers Squibb Company, Cipla, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc., Johnson and Johnson, Merck & Co, Inc., Pfizer Inc., and Viatris Inc., are some of the major anti-retroviral drugs companies worldwide.